Floatz logo

su011248

Kidney Carcinoma

National Cancer Institute (NCI)Phase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the Kidney Carcinoma cohort.

Asset / SponsorPhaseRating
Tas-102
National Cancer Institute (NCI)
Phase 2B
Crizotinib
National Cancer Institute (NCI)
Phase 2CCC
Larotrectinib
National Cancer Institute (NCI)
Phase 2CCC
Osimertinib
National Cancer Institute (NCI)
Phase 2CCC
Fexagratinib
National Cancer Institute (NCI)
Phase 2CCC

View all 27 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →